Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?

Journal of Gastroenterology

Volumn 34, Issue 4, 1999, Pages 435-440

  Soga, Tadashi ^a   Matsuura, Minoru ^a   Kodama, Yuzo ^a   Fujita, Tsuyoshi ^a   Sekimoto, Ikufumi ^a   Nishimura, Kazumasa ^a   Yoshida, Syunichi ^a   Kutsumi, Hiromu ^a,b   Fujimoto, Sotaro ^a,b  

^a Akashi Municipal Hospital   (Japan)

^b KYOTO FIRST RED CROSS HOSPITAL   (Japan)

Author keywords

H2RA; Los Angeles classification; PPI; Reflux esophagitis

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE TRACT ENDOSCOPY; DISEASE SEVERITY; DRINKING BEHAVIOR; DRUG CHOICE; DRUG EFFICACY; FEMALE; FOLLOW UP; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; REMISSION;

ALCOHOL DRINKING; CASE-CONTROL STUDIES; ENDOSCOPY, DIGESTIVE SYSTEM; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; FAMOTIDINE; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0032817260     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350050292     Document Type: Article

References (16)

1. Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(Suppl 1):9-14.
2. Sangaletti O, Pace F, Bianchi Porro G. Gastroesophageal reflux in patients with esophagitis "resistant" to H2-antagonists (abstract). Gastroenterology 1989;96:439.
3. Robinson M, Maton PN, Allen ML, Humphries TJ, Mcintosh D, Cagliola AJ, et al. Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastrooesophageal reflux. Aliment Pharmacol Ther 1991;5:645-51.
4. Sharma BK, Walt PR, Pounder RE, Gomes M, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984;25:957-64.
5. Ducrotte P, Guillemot F, Elouaer-Blanc L, Hirschauer C, Thorel JM, Petit A, et al. Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: a cross-over study. Am J Gastroenterol 1994;89:717-21.
6. Fiorucci S, Santucci L, Morelli A. Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis. Am J Gastroenterol 1990;85:1458-62.
7. Bate CM, Keeling PWN, Morain CO, Wilkinson SP, Foster DN, Mountford RA, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluation. Gut 1990;31:968-72.
8. Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986;21:837-47.
9. Havelund T, Laursen LS, Lauritsen K. Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease. Scand J Gastroenterol 1994;29(Suppl 201):69-73.
10. Caestecker JS, Bennett JR. The role of endoscopy in gastro-oesophageal reflux disease. Guidelines for management of symptomatic gastro-oesophageal reflux disease. London: Science Press; 1998. p. 15-23.
11. Kuipers EJ, Ludell L, Klinkenberg-Knol EC, Havu N, Festen HPM, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
12. Xia HH, Talley NJ. Helicobacter pylori infection, reflux esophagitis, and atrophic gastritis: an unexplored triangle. Am J Gastroenterol 1998;93:394-400.
13. Koster E. Indications for HP eradication: gastro-esophageal reflux disease. Acta Gastroenterol Belg 1998;61:313-5.
14. Venables TL, Newland RD, Patel AC, Hole J, Copeman MB, Turbitt ML, et al. Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol 1997;32:627-32.
15. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
16. Carlsson R, Galmiche JP, Dent J, Lundel L, Prison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997;11:473-82.